• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

《心力衰竭中钠-葡萄糖协同转运蛋白2抑制剂：潜在作用机制、不良反应及未来发展》勘误

Corrigendum to: Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments.

作者信息

Tamargo Juan

机构信息

Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, CIBERCV Madrid, Spain.

出版信息

Eur Cardiol. 2019 Dec 18;14(3):201. doi: 10.15420/ecr.2019.14.3.CG1. eCollection 2019 Dec.

DOI:10.15420/ecr.2019.14.3.CG1
PMID:31933693
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6955741/
Abstract

[This corrects the article DOI: 10.15420/ecr.2018.34.2.].

摘要

[本文更正了文章的数字对象标识符：10.15420/ecr.2018.34.2。]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e87/6955741/c9d37f2c538a/ecr-14-201-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e87/6955741/c9d37f2c538a/ecr-14-201-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e87/6955741/c9d37f2c538a/ecr-14-201-g001.jpg

相似文献

1
Corrigendum to: Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments.《心力衰竭中钠-葡萄糖协同转运蛋白2抑制剂：潜在作用机制、不良反应及未来发展》勘误
Eur Cardiol. 2019 Dec 18;14(3):201. doi: 10.15420/ecr.2019.14.3.CG1. eCollection 2019 Dec.
2
Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments.心力衰竭中的钠-葡萄糖协同转运蛋白2抑制剂：潜在作用机制、不良反应及未来发展
Eur Cardiol. 2019 Apr;14(1):23-32. doi: 10.15420/ecr.2018.34.2.
3
CORRIGENDUM FOR "Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM".《胰高血糖素样肽-1受体激动剂与钠-葡萄糖协同转运蛋白抑制剂治疗2型糖尿病的对比》勘误
J Endocr Soc. 2020 Nov 18;4(12):bvaa134. doi: 10.1210/jendso/bvaa134. eCollection 2020 Dec 1.
4
Sodium-glucose cotransporter 2 inhibitors' mechanisms of action in heart failure.钠-葡萄糖协同转运蛋白2抑制剂在心力衰竭中的作用机制。
World J Diabetes. 2020 Jul 15;11(7):269-279. doi: 10.4239/wjd.v11.i7.269.
5
Letter by Koh Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".科关于文章《钠-葡萄糖协同转运蛋白2抑制剂起始治疗患者与其他降糖药物相比心力衰竭和死亡风险更低：CVD-REAL研究（钠-葡萄糖协同转运蛋白2抑制剂新使用者心血管结局的比较有效性）》的信
Circulation. 2018 Feb 27;137(9):984-985. doi: 10.1161/CIRCULATIONAHA.117.030650.
6
Letter by Taegtmeyer and Karlstaedt Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".泰格特迈尔和卡尔施泰特就文章《钠-葡萄糖协同转运蛋白2抑制剂起始治疗患者与其他降糖药物相比心力衰竭和死亡风险更低：CVD-REAL研究（钠-葡萄糖协同转运蛋白2抑制剂新使用者心血管结局的比较有效性）》所写的信
Circulation. 2018 Feb 27;137(9):986-987. doi: 10.1161/CIRCULATIONAHA.117.031193.
7
Letter by Tampaki et al Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".坦帕基等人就文章《与其他降糖药物相比，起始使用钠-葡萄糖协同转运蛋白2抑制剂的患者发生心力衰竭和死亡的风险更低：CVD-REAL研究（钠-葡萄糖协同转运蛋白2抑制剂新使用者心血管结局的比较有效性）》所写的信
Circulation. 2018 Feb 27;137(9):982-983. doi: 10.1161/CIRCULATIONAHA.117.030339.
8
Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".科西博罗德等人对关于“与其他降糖药物相比，起始使用钠-葡萄糖协同转运蛋白2抑制剂的患者心力衰竭和死亡风险更低：CVD-REAL研究（钠-葡萄糖协同转运蛋白2抑制剂新使用者心血管结局的比较有效性）”一文的信件的回复
Circulation. 2018 Feb 27;137(9):989-991. doi: 10.1161/CIRCULATIONAHA.117.031847.
9
Letter by Jin-shan and Xue-bin Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".金山和学斌就文章《与其他降糖药物相比，起始使用钠-葡萄糖协同转运蛋白2抑制剂的患者发生心力衰竭和死亡的风险更低：CVD-REAL研究（钠-葡萄糖协同转运蛋白2抑制剂新使用者心血管结局的比较有效性）》所写的信
Circulation. 2018 Feb 27;137(9):988. doi: 10.1161/CIRCULATIONAHA.117.031407.
10
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.钠-葡萄糖共转运蛋白 2 抑制剂治疗心力衰竭患者的效果：一种新作用机制的提出。
JAMA Cardiol. 2017 Sep 1;2(9):1025-1029. doi: 10.1001/jamacardio.2017.2275.

引用本文的文献

1
Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.钠-葡萄糖共转运蛋白 2 抑制剂在心力衰竭患者中的作用：一个难以捉摸的机制。
Ann Med. 2020 Aug;52(5):178-190. doi: 10.1080/07853890.2020.1767298. Epub 2020 May 22.